New shot aims to tame dangerous liver virus
NCT ID NCT06505928
Summary
This study is testing whether an experimental injection called Hepalatide (L47) can help control Hepatitis D, a serious liver infection. It will enroll 90 adults with stable liver function to receive either a low dose, a high dose, or delayed treatment for 48 weeks. The main goal is to see if the treatment significantly reduces the virus level and returns a key liver enzyme to normal.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Center for Communicable Diseases
Ulaanbaatar, Mongolia
-
National cancer canter of Monglia
Ulaanbaatar, 13370, Mongolia
Conditions
Explore the condition pages connected to this study.